Literature DB >> 19556286

Emerging roles of chemokines in prostate cancer.

David Vindrieux1, Pauline Escobar, Gwendal Lazennec.   

Abstract

Prostate cancer (PCa) represents the second leading cause of death among all cancer types in men in Europe and North America. Among the factors suspected to control PCa, incidence and progression, chemokines, and their receptors are now intensively studied. Chemokines are produced by tumor cells and also by the stromal microenvironment, both in the primary tumor site and in distant metastatic locations. The wide and differential distribution of chemokines and their receptors account for the pleiotropic actions of chemokines in PCa, including the modulation of growth, angiogenesis, invasion, metastasis, and hormone escape. This review will focus on the roles and the mechanisms of action and regulation of chemokines in the different steps of PCa development and will discuss the novel strategies that are currently envisioned to target chemokines in PCa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556286     DOI: 10.1677/ERC-09-0109

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  62 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.

Authors:  Courtney R LaValle; Liyong Zhang; Shuping Xu; Julie L Eiseman; Q Jane Wang
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

3.  Serum cytokine profiles in patients with prostate carcinoma.

Authors:  Eri Tazaki; Nobuaki Shimizu; Ryota Tanaka; Masakazu Yoshizumi; Hiroshi Kamma; Shigeru Imoto; Tomoyuki Goya; Kunihisa Kozawa; Atsuyoshi Nishina; Hirokazu Kimura
Journal:  Exp Ther Med       Date:  2011-06-16       Impact factor: 2.447

4.  MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Authors:  Dawid G Nowak; Hyejin Cho; Tali Herzka; Kaitlin Watrud; Daniel V DeMarco; Victoria M Y Wang; Serif Senturk; Christof Fellmann; David Ding; Tumas Beinortas; David Kleinman; Muhan Chen; Raffaella Sordella; John E Wilkinson; Mireia Castillo-Martin; Carlos Cordon-Cardo; Brian D Robinson; Lloyd C Trotman
Journal:  Cancer Discov       Date:  2015-03-31       Impact factor: 39.397

Review 5.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

6.  Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.

Authors:  Hina Mir; Neeraj Kapur; Rajesh Singh; Guru Sonpavde; James W Lillard; Shailesh Singh
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 7.  Inflammation and prostate cancer: friends or foe?

Authors:  Gianluigi Taverna; Elisa Pedretti; Giuseppe Di Caro; Elena Monica Borroni; Federica Marchesi; Fabio Grizzi
Journal:  Inflamm Res       Date:  2015-03-19       Impact factor: 4.575

8.  Targeting chemokine pathways in esophageal adenocarcinoma.

Authors:  Makardhwaj S Shrivastava; Zulfiqar Hussain; Orsolya Giricz; Niraj Shenoy; Rahul Polineni; Anirban Maitra; Amit Verma
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  The CXCL12/CXCR4 autocrine loop increases the metastatic potential of non-small cell lung cancer in vitro.

Authors:  Xiaofeng Dai; Zhifu Mao; Jie Huang; Songping Xie; Hao Zhang
Journal:  Oncol Lett       Date:  2012-10-10       Impact factor: 2.967

10.  Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers.

Authors:  Kangkang Zhi; Xiaojun Shen; Hao Zhang; Jianwei Bi
Journal:  J Exp Clin Cancer Res       Date:  2010-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.